Harnessing the power of the immune system to destroy cancer has dominated the biotech industry over the past decade. And for good reason: CAR-T therapies, checkpoint inhibitors, oncolytic viruses, and other next-generation immunotherapies can be incredibly effective at treating cancer — in some patients.
That last phrase is the big caveat of immuno-oncology therapies: They don’t work in everyone, but only in very specific subsets of patients. While a promising way to make these therapies work in broader patient populations is to combine different immuno-oncology therapies, we first need to understand which patients will respond to treatment and why.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
